Johnson & Johnson has settled a record $5.5 billion to settle thousands of litigations over its talc-based goods, Because of this bringing to an end one of the largest and highly scrutinized product liability cases to date. This settlement is seen as a milestone for the healthcare company that now aims to put behind it years of legal drama and concentrate on its pharmaceutical and medical technology operations.
The litigation accused Johnson & & Johnson of tampering its talc-based baby powder and other products over years causing cancer. In total, ten of thousands of people pressed charges during last several years claiming that long-term use of J & J talc products led to grave health problems including mesothelioma and ovarian cancer. The company repeatedly has denied any allegations and argued that century worth of scientific studies backs fact that its talc products are safe for production use.
The firm, while settling for billions of dollars, still denies any allegations of unsafe products or products that caused cancer. While joining the multi-billion dollar settlement, it has opted to settle and dissolve litigation without an enduring court battle that could last long for many years. As advisory attorneys observed, Plaintiffs believed that big corporations tend to settle, in order not to be costly and risky, to reduce uncertainty and challenges in the coming future and limit future lawsuits against them, and to redress or compensate using an orderly claims process.
The settlement seems to come after years of litigation on this issue. A host of suits over thousands of individual claims have been filed and litigated throughout the U.S.
Courts over the years and the verdicts by those courts have been inconsistentsome in favor of the plaintiffs and others in favor of the defendant company. This uncertainty fomented the need for a negotiated comprehensive solution. Johnson & Johnson has been trying to change its ways for how it handles the litigation for a number of years.
In the past, such litigating strategies as trying to resolve the claims through bankruptcy proceedings involving a subsidiary failed in the courts. This latest settlement is another approach that hopefully will satisfy more claimants and provide certainty for all. Johnson & Johnson stopped selling talc-based baby powder in North America a number of years ago and instead introduced a new cornstarch-based option worldwide; Though, it maintains that this change was not due to safety concerns but rather shifting consumer trends.
To this day, the company still sells baby powder made with cornstarch, not talc. For many plaintiffs and their loved ones, the offer of a settlement may be perceived as the only chance to be compensated after years of litigation. The settlement intends to create a predetermined means for the assessment and resolution of eligible claims, with final funding subject to court approval and determined by the terms of the settlement program.
While the financial repercussions of the settlement are sizable, analysts remain optimistic that Johnson & Johnson is still well fortified by the strength of its diversified healthcare business. Sales from prescription drugs, medical devices and cutting-edge healthcare technology provide Johnson & Johnson with revenues large enough to cover the bulk of legal costs and still allow for substantial capital devoted to research and development.
